CTAD Notebook: Novo’s Semaglutide Data Show No Difference From Placebo In AD

EVOKE/EVOKE+ Revealed Similar Rates Of Cognitive Decline

 
• By Mandy Jackson
  
More detailed data for semaglutide in Alzheimer's disease will be presented next year (Shutterstock)

More from Neurological

More from Scrip